- Home
- ACRS vs TLRY Comparison
ACRS vs TLRY Comparison
Compare ACRS & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | TLRY |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.9M | 688.9M |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ACRS | TLRY |
|---|---|---|
| Price | $4.52 | $4.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $10.20 | ★ $72.33 |
| AVG Volume (30 Days) | 1.0M | ★ 3.3M |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | $4.24 | $19.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.34 | $0.36 |
| 52 Week High | $5.15 | $15.70 |
Technical Indicators
Market Signals| Indicator | ACRS | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 33.20 |
| Support Level | $4.13 | $1.12 |
| Resistance Level | $4.73 | $5.71 |
| Average True Range (ATR) | 0.27 | 0.27 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 56.88 | 10.66 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.